SCHEMBL810679

SCHEMBL810679

Cc1ccc2c(Nc3cc(NCc4cccs4)ccc3Sc3ccc(O)cc3)ncnc2n1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIM1 P11309 1/20 0.58
AKT2 P31751 1/20 0.58
L3MBTL1 Q9Y468 1/20 0.41
EGFR P00533 2/20 0.41
NPC1 O15118 3/20 0.36
SMN1; SMN2 Q16637 3/20 0.36
KDM4E B2RXH2 3/20 0.36
RAB9A P51151 3/20 0.36
ALDH1A1 P00352 2/20 0.36
HTT P42858 1/20 0.36
KHK P50053 1/20 0.36
LMNA P02545 3/20 0.36
MAPK1 P28482 2/20 0.35
MAPT P10636 1/20 0.35
CLK4 Q9HAZ1 2/20 0.35
TSHR P16473 2/20 0.35
CYP1A2 P05177 1/20 0.35
CYP3A4 P08684 1/20 0.35
CYP2D6 P10635 1/20 0.35
CYP2C9 P11712 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL810444 0.87 PIM1 (0.63) PIM1AKT2EGFRMAPTGAA
SCHEMBL810885 0.86 PIM1 (0.56) PIM1AKT2EGFRNPC1GAA
SCHEMBL810865 0.85 PIM1 (0.58) PIM1AKT2SMN1; SMN2KDM4ERAB9A
SCHEMBL811087 0.84 PIM1 (0.65) PIM1AKT2EGFRGAAMEN1
SCHEMBL811023 0.84 PIM1 (0.56) PIM1AKT2EGFRCLK4GAA
SCHEMBL810855 0.84 PIM1 (0.64) PIM1AKT2EGFRALDH1A1LMNA
SCHEMBL810627 0.84 PIM1 (0.61) PIM1AKT2EGFRNPC1HTT
SCHEMBL811431 0.80 PIM1 (0.66) PIM1AKT2EGFRKDM4EHTT
SCHEMBL811387 0.79 PIM1 (0.65) PIM1AKT2EGFRGAAMEN1
SCHEMBL811176 0.78 PIM1 (0.60) PIM1AKT2EGFRNPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1971611-B1 ANTI-VIRAL COMPOUNDS ABBOTT LAB (US) 2012-10-10 EP disclosed
EP-2345652-A1 Antiviral compounds Abbott Laboratories (US) 2011-07-20 EP disclosed
US-7915411-B2 Anti-viral compounds ABBOTT LABORATORIES (US) 2011-03-29 US disclosed
EP-1971611-A1 ANTI-VIRAL COMPOUNDS Abbott Laboratories (US) 2008-09-24 EP disclosed
US-20070197558-A1 ANTI-VIRAL COMPOUNDS ABBVIE INC. 2007-08-23 US disclosed
WO-2007081517-A2 ANTI-VIRAL COMPOUNDS ABBOTT LABORATORIES (US) 2007-07-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070197558-A1 ANTI-VIRAL COMPOUNDS HAVCR2, MAVS, EIF2AK2 PIM1 2963/4885AKT2 3903/4885L3MBTL1 2884/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.